Payment for the Substitute Target. If a Substitute Target is substituted in as an Oncology Target after [***] status for a Discontinued Target under this Section 3.3.7, AstraZeneca will pay Isis $[***] within 30 days after such Substitute Target is substituted in as an Oncology Target.
Appears in 2 contracts
Sources: Collaboration, License and Development Agreement (Ionis Pharmaceuticals Inc), Collaboration, License and Development Agreement (Isis Pharmaceuticals Inc)